0%, 4.3%, 3.5%, and 1.7 for CREOP, CAS, hCEA, and lCEA, respectively. Ipsilateral stroke was 0%, 4.3%, 1.9%, and 0% for the four groups. For the same four groups, mortality was 0%, 2.1%, 1.7%, and 1.7%; any stroke was 0%, 4.3%, 1.7%, and 0%; and MI was 6.9%, 0%, 3.5%, and 1.7% (P > .05). Results were similar between CREOP and the other three groups regardless of symptoms (Table) . In asymptomatic patients, hospital stay was the longest for CREOP (P > .05). Early complications were higher in CREOP in both asymptomatic (29% vs 5.9%; P ¼ .03) and symptomatic patients (67% vs 25%; P ¼ .03) compared to lCEA, but similar to hCEA. Over an average follow-up of 5.2 6 4.1 years, 5-year composite stroke and death was 31%, 20%, 40%, and 15% for CREOP, CAS, hCEA, and lCEA, respectively. Five-year ipsilateral stroke was 0%, 4.3%, 7.4%, and 0% (P > .05). However, composite stroke and death was higher in symptomatic CREOP patients compared to lCEA (P ¼ .049, Table) . There were no early or late differences in primary end points between CREOP and CAS.
Conclusions: Composite stroke and death, and ipsilateral stroke, are similar between reoperative carotid surgery and CAS for recurrent carotid stenosis. However, redo carotid surgery can be performed safely in both asymptomatic and symptomatic patients, with similar early stroke or death as primary CEA. CAS carries low early stroke or death in asymptomatic patients. There were too few symptomatic patients to determine its risk.
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